Inari Medical, Inc. NARI
We take great care to ensure that the data presented and summarized in this overview for Inari Medical, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding NARI
View all-
Black Rock Inc. New York, NY8.36MShares$669 Million0.01% of portfolio
-
Credit Suisse Ag Zurich, V81.29MShares$103 Million0.06% of portfolio
-
Eaton Vance Management Boston, MA687KShares$55 Million0.07% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL458KShares$36.6 Million0.01% of portfolio
-
Berry Street Capital Management LLP London, X087.5KShares$7 Million1.68% of portfolio
-
Raymond James & Associates St Petersburg, FL14.8KShares$1.18 Million0.0% of portfolio
-
Brinker Capital Investments, LLC12.1KShares$966,9970.02% of portfolio
-
First Republic Investment Management, Inc. San Francisco, CA8.29KShares$663,1910.0% of portfolio
-
Millrace Asset Group, Inc.6.94KShares$554,9910.29% of portfolio
-
Putnam Investments LLC Boston, MA6.4KShares$511,7280.0% of portfolio
Latest Institutional Activity in NARI
Top Purchases
Top Sells
About NARI
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.
Insider Transactions at NARI
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 19
2025
|
Robert Keith Warner Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
12,149
-100.0%
|
-
|
|
Feb 19
2025
|
Catherine M. Szyman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
22,429
-100.0%
|
-
|
|
Feb 19
2025
|
Thomas Tu Chief Medical Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
478,767
-100.0%
|
-
|
|
Feb 19
2025
|
Thomas Tu Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
7,406
+1.52%
|
-
|
|
Feb 19
2025
|
Jonathan D Root Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
335
-100.0%
|
-
|
|
Feb 19
2025
|
Jonathan D Root Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
541,149
-100.0%
|
-
|
|
Feb 19
2025
|
Karen Silva Principal Accounting Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
14,719
-100.0%
|
-
|
|
Feb 19
2025
|
Kevin T Strange Chief Financial Officer |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
67,502
-100.0%
|
-
|
|
Feb 19
2025
|
Dana G Mead Jr. Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
11,148
-100.0%
|
-
|
|
Feb 19
2025
|
Donald B Milder Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
2,831,714
-100.0%
|
-
|
|
Feb 19
2025
|
Donald B Milder Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
259,126
-100.0%
|
-
|
|
Feb 19
2025
|
William Hoffman Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
238,987
-100.0%
|
-
|
|
Feb 19
2025
|
Andrew Hykes President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
717,637
-100.0%
|
-
|
|
Feb 19
2025
|
Andrew Hykes President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,393
+2.76%
|
-
|
|
Feb 19
2025
|
Andrew Hykes President and CEO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
5,650
-100.0%
|
-
|
|
Feb 19
2025
|
Cynthia L Lucchese Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
38,429
-100.0%
|
-
|
|
Feb 19
2025
|
Rebecca Chambers Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
9,684
-100.0%
|
-
|
|
Feb 10
2025
|
Andrew Hykes President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
194,538
+8.09%
|
$389,076
$2.45 P/Share
|
|
Feb 10
2025
|
Thomas Tu Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
148,004
+12.46%
|
$444,012
$3.46 P/Share
|
|
Feb 04
2025
|
Kevin T Strange Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
21,102
+23.82%
|
-
|
Last 12 Months Summary
| Exercise of conversion of derivative security | 351K shares |
|---|---|
| Grant, award, or other acquisition | 158K shares |
| Disposition due to a tender of shares in a change of control transaction | 5.25M shares |
|---|---|
| Payment of exercise price or tax liability | 21.5K shares |
| Open market or private sale | 527K shares |